What does this paper add to the literature?Transanal total mesorectal excision (TaTME) is an emerging surgical technique for rectal cancer resection. This study is the first to provide results of a prospective multicentre cohort study comparing TaTME and laparoscopic total mesorectal excision. TaTME is a safe and feasible approach for rectal cancer resection. TaTME obtained similar postoperative morbidity and required fewer conversions.

Introduction {#codi14601-sec-0006}
============

Total mesorectal excision (TME) is the gold standard for rectal resection. This surgical technique, involving resection of the fatty envelope surrounding the rectum, has substantially contributed to local control and survival of rectal cancer [1](#codi14601-bib-0001){ref-type="ref"}, [2](#codi14601-bib-0002){ref-type="ref"}.

Minimally invasive techniques have been introduced for rectal surgery. Several randomized controlled trials have shown that oncological outcomes are comparable for open and laparoscopic surgery for rectal cancer. The COREAN trial has shown short‐term benefits for laparoscopic surgery compared to open surgery and an equivalent quality of oncological resection [3](#codi14601-bib-0003){ref-type="ref"}. In the long term, disease‐free survival was similar for the two techniques [4](#codi14601-bib-0004){ref-type="ref"}. In addition, The COLOR‐II trial has confirmed that laparoscopic and open surgery for rectal cancer provide similar long‐term outcomes [5](#codi14601-bib-0005){ref-type="ref"}.

Recently, it has been shown that age above 65 years, a body mass index (BMI) greater than 25 and tumour location close to the anal verge are risk factors for the conversion from laparoscopic to open surgery [6](#codi14601-bib-0006){ref-type="ref"}. In addition, factors such as a narrow pelvis or limited views of the distal rectum make the laparoscopic approach difficult. These considerations emphasize the need for a new minimally invasive technique that overcomes the limitations of laparoscopy.

Transanal total mesorectal excision (TaTME) may be the solution. Since its introduction in 2010, TaTME has been shown to be a feasible and safe technique for rectal cancer resections and has subsequently achieved widespread acceptance [7](#codi14601-bib-0007){ref-type="ref"}, [8](#codi14601-bib-0008){ref-type="ref"}. Nevertheless, to date, most evidence has been obtained from cohort studies with small sample sizes and retrospective design [9](#codi14601-bib-0009){ref-type="ref"}, [10](#codi14601-bib-0010){ref-type="ref"}, [11](#codi14601-bib-0011){ref-type="ref"}, [12](#codi14601-bib-0012){ref-type="ref"}, [13](#codi14601-bib-0013){ref-type="ref"}. Therefore, this study is important because it is the first to provide results of a prospective multicentre cohort study. The aim of the study was to compare postoperative morbidity between TaTME and laparoscopic total mesorectal excision (LaTME).

Method {#codi14601-sec-0007}
======

The study was designed as a subgroup analysis of a prospective multicentre cohort study, the APPEAL‐II study. Ten hospitals in the Netherlands and Belgium participated. The study was approved by the medical ethics committee of the Erasmus University Medical Center in the Netherlands and of the University Hospital Leuven in Belgium. We also obtained approval from local ethics committees of the participating hospitals. This prospective cohort was established between August 2015 and October 2017. Patients aged 18 years and older who underwent partial mesorectal excision (PME) or TME with construction of a colorectal or coloanal anastomosis were eligible for inclusion. We excluded pregnant women and patients who underwent emergency procedures. All patients received a pelvic drain during surgery that was kept in place for at least the first three postoperative days. Drain fluid was obtained for further analysis according to the study protocol (<https://doi.org/10.1186/isrctn84052649>). Follow‐up, for the purposes of this study, was completed at the first visit at the outpatient clinic after hospital discharge. Informed consent was obtained from all patients. For this subgroup analysis, we selected patients who underwent TaTME or LaTME for rectal cancer. Patient selection for TaTME or LaTME was at discretion of the surgeon.

Baseline characteristics \[age, gender, BMI, smoking, alcohol abuse (\> 14 units per week), American Society of Anesthesiologists (ASA) score, tumour location, neoadjuvant radiotherapy, neoadjuvant chemotherapy, pathological TNM staging\] and surgical characteristics \[duration of surgery, duration of anaesthesia, conversion, construction of anastomosis, configuration of anastomosis, diverting ileostomy, circumferential resection margin (CRM), distal resection margin (DRM)\] were prospectively registered. CRM was considered positive when the margin was \< 1 mm and for the DRM this was \< 1 cm [14](#codi14601-bib-0014){ref-type="ref"}.

Outcome measures {#codi14601-sec-0008}
----------------

The outcome measures of this analysis were postoperative complications, readmissions, reoperations, conversions and mortality. Stoma reversals were not considered as reoperations unless they were due to stoma complications. Anastomotic leakage was defined as clinically manifest insufficiency of the anastomosis leading to a clinical state requiring re‐intervention (i.e. Grade B/C) [15](#codi14601-bib-0015){ref-type="ref"}. Anastomotic leakage was confirmed by endoscopy, CT scan and/or contrast enema or reoperation. Re‐intervention for anastomotic leakage consisted of therapeutic antibiotics, (endoscopic) drainage or a surgical re‐intervention. Presacral abscesses were classified as anastomotic leakage if extravasation of the colonic contrast was visible on radiological imaging. Fistulas attached to the anastomosis on CT scan were also classified as anastomotic leakage. Postoperative complications were classified according to the Clavien--Dindo classification system and Grade II or higher was considered to be a severe complication [16](#codi14601-bib-0016){ref-type="ref"}, [17](#codi14601-bib-0017){ref-type="ref"}. In addition, the comprehensive complication index (CCI) for every patient was calculated using <http://www.assessurgery.com> [18](#codi14601-bib-0018){ref-type="ref"}.

Statistical analysis {#codi14601-sec-0009}
--------------------

Continuous variables were described as median ± interquartile range and compared with the Mann--Whitney *U* test. Categorical variables were described as percentages and compared using the chi‐squared test or Fisher\'s exact test when needed. Patients were matched based on the propensity score derived from a logistic regression model with approach as dependent covariate and baseline characteristics with *P* value \< 0.1 as independent covariates. In addition, a multivariate penalized logistic/linear regression model was built to investigate the adjusted association between the surgical approach and the outcome measures adjusted for the aforementioned risk factors in the unmatched dataset (age, gender, BMI, tumour location, pathological tumour stage, neoadjuvant radiotherapy, neoadjuvant chemotherapy, diverting ileostomy, approach). All clinically relevant variables were added to the model. Statistical significance was defined as *P* value \< 0.050. All analyses were performed using [spss]{.smallcaps} ^®^ software 21.0 (IBM, Armonk, New York, USA) or (R software, <http://www.r-project.org>).

Results {#codi14601-sec-0010}
=======

This prospective cohort study of patients undergoing PME or TME included 301 patients. For this analysis, we excluded 74 patients who underwent PME or who had an open approach and seven patients who were operated upon for reasons other than rectal cancer. In total, 220 patients were selected (Fig. [1](#codi14601-fig-0001){ref-type="fig"}). The median follow‐up was 27.0 days (interquartile range 19.0--34.0 days).

![Flowchart of patient selection.](CODI-21-767-g001){#codi14601-fig-0001}

Table [1](#codi14601-tbl-0001){ref-type="table"} shows prematching baseline characteristics of the overall study population of 220 patients. Age, tumour location, pathological T staging and neoadjuvant chemotherapy were used to calculate the propensity score. After matching for propensity score, 96 patients were eligible for analysis.

###### 

Demographic characteristics for patients undergoing LaTME and TaTME

                                                    TaTME 119 (54.1%)   LaTME 101 (45.9%)   Missing (%)   *P* value
  ------------------------------------------------- ------------------- ------------------- ------------- -----------------------------------------------------
  Baseline characteristics                                                                                
  Age, median (IQR), year                           62.0 (56.0--67.0)   66.0 (59.5--73.0)   0 (0.0)       **0.003**
  Gender                                                                                                  
  Male                                              86 (72.3%)          64 (63.4%)          0 (0.0)       0.158
  Female                                            33 (27.7%)          37 (36.6%)                        
  BMI, median (IQR), kg/m^2^                        26.6 (23.7--29.7)   25.2 (23.2--28.7)   1 (0.5)       0.162
  Smoking                                                                                                 
  Yes                                               15 (12.7%)          11 (11.5%)          6 (2.7)       0.780
  No                                                103 (87.3%)         85 (88.5%)                        
  Alcohol abuse                                                                                           
  Yes                                               16 (13.6%)          11 (11.7%)          8 (3.6)       0.687
  No                                                102 (86.4%)         83 (88.3%)                        
  Bowel preparation                                                                                       
  Yes                                               116 (97.5%)         82 (92.1%)          12 (5.5)      0.102[\*](#codi14601-note-0003){ref-type="fn"}
  No                                                3 (2.5%)            7 (7.9%)                          
  Previous abdominal surgery                                                                              
  Yes                                               37 (31.1%)          35 (35.0%)          1 (0.5)       0.540
  No                                                82 (68.9%)          65 (65.0%)                        
  ASA score                                                                                               
  I                                                 11 (9.2%)           16 (16.0%)          1 (0.5)       0.355[\*](#codi14601-note-0003){ref-type="fn"}
  II                                                77 (64.7%)          64 (64.0%)                        
  III                                               30 (25.2%)          19 (19.0%)                        
  IV                                                1 (0.8%)            1 (1.0%)                          
  Tumour distance to anal verge, median (IQR), cm   5.0 (2.1--10.0)     12.0 (9.0--15.0)    12 (5.5)      **\< 0.001**
  pT stage                                                                                                
  pT0                                               21 (17.8%)          6 (6.0%)            7 (3.1)       **0.027** [\*](#codi14601-note-0003){ref-type="fn"}
  pT1                                               16 (13.6%)          19 (19.0%)                        
  pT2                                               36 (30.5%)          26 (26.0%)                        
  pT3/4                                             42 (35.6%)          47 (47.0%)                        
  pN stage                                                                                                
  pN0                                               83 (69.7%)          68 (67.3%)          7 (3.1)       0.292
  pN1                                               17 (14.3%)          22 (21.8%)                        
  pN2                                               14 (11.8%)          8 (7.9%)                          
  pN3                                               0 (0.0%)            1 (1.0%)                          
  Neoadjuvant radiotherapy                                                                                
  Yes                                               67 (56.3%)          60 (60.0%)          1 (0.5)       0.581
  Short‐course                                      14                  34                                
  Long‐course                                       47                  25                                
  No                                                52 (43.7%)          40 (40.0%)                        
  Neoadjuvant chemotherapy                                                                                
  Yes                                               52 (43.7%)          28 (28.0%)          1 (0.5)       **0.016**
  No                                                67 (56.3%)          72 (72.0%)                        

ASA, American Society of Anesthesiologists; BMI, body mass index; IQR, interquartile range; LaTME, laparoscopic total mesorectal excision; TaTME, transanal total mesorectal excision.

Fisher\'s exact test.

Bold values indicates *P* value \<0.05.

John Wiley & Sons, Ltd

Table [2](#codi14601-tbl-0002){ref-type="table"} shows postmatching baseline characteristics of 48 patients undergoing TaTME and 48 patients undergoing LaTME. Patients undergoing LaTME received neoadjuvant radiotherapy more often (43.8% *vs* 64.6%, *P* = 0.041). The other baseline characteristics were not statistically significantly different for TaTME and LaTME. Duration of surgery and anaesthesia were both significantly longer for TaTME (221 *vs* 180 min, *P* \< 0.001; 264 *vs* 217 min, *P* \< 0.001). TaTME was not converted to laparotomy whilst surgery in five patients undergoing LaTME was converted to laparotomy (0.0% *vs* 10.4%, *P* = 0.056; Table [3](#codi14601-tbl-0003){ref-type="table"}). Reasons for conversion were adhesions, obesity, bleeding and insufficient bowel length for stoma creation.

###### 

Postmatching baseline characteristics

                                      TaTME 48            LaTME 48            Missing (%)   *P* value
  ----------------------------------- ------------------- ------------------- ------------- ------------------------------------------------
  Age, median (IQR), year             65.0 (56.8--71.0)   64.0 (59.3--73.0)   0 (0.0)       0.752
  Gender                                                                                    
  Male                                33 (68.8%)          32 (66.7%)                        0.827
  BMI, median (IQR), kg/m^2^          27.0 (24.5--30.7)   26.1 (24.0--29.0)   1 (1.0)       0.221
  Smoking                             5 (10.4%)           6 (12.5%)           5 (5.2)       0.661
  Alcohol abuse                       7 (14.6%)           2 (4.2%)            5 (5.2)       0.164[\*](#codi14601-note-0005){ref-type="fn"}
  ASA score                                                                                 
  I                                   4 (8.3%)            6 (12.5%)           0 (0.0)       0.953[\*](#codi14601-note-0005){ref-type="fn"}
  II                                  29 (60.4%)          28 (58.3%)                        
  III                                 14 (29.2%)          13 (27.1%)                        
  IV                                  1 (2.1%)            1 (2.1%)                          
  Tumour location, median (IQR), cm   10.0 (6.0--10.8)    9.5 (7.0--12.0)     0 (0.0)       0.459
  Neoadjuvant radiotherapy            21 (43.8%)          31 (64.6%)          0 (0.0)       **0.041**
  Short‐course                        5 (10.4%)           16 (33.3%)                        
  Long‐course                         15 (31.3%)          14 (29.2%)                        
  Neoadjuvant chemotherapy            14 (29.2%)          16 (33.3%)          0 (0.0)       0.660
  pT stage                                                                                  
  pT0                                 3 (6.3%)            2 (4.2%)            0 (0.0)       0.973[\*](#codi14601-note-0005){ref-type="fn"}
  pT1                                 7 (14.6%)           7 (14.6%)                         
  pT2                                 15 (31.3%)          14 (29.2%)                        
  pT3/4                               23 (47.9%)          25 (52.1%)                        
  pN stage                                                                                  
  pN0                                 32 (66.7%)          34 (70.8%)          0 (0.0)       0.660
  pN+                                 16 (33.3%)          14 (29.2%)                        

ASA, American Society of Anesthesiologists; BMI, body mass index; IQR, interquartile range; LaTME, laparoscopic total mesorectal excision; TaTME, transanal total mesorectal excision.

Fisher\'s exact test.

Bold values indicates *P* value \<0.05.

John Wiley & Sons, Ltd

###### 

Postmatching surgical characteristics

                                               TaTME 48                 LaTME 48               Missing (%)   *P* value
  -------------------------------------------- ------------------------ ---------------------- ------------- --------------------------------------------------------
  Duration of surgery, median (IQR), min       221.0 (187.50--263.50)   180.0 (141.0--205.0)   3 (3.1)       **\< 0.001**
  Duration of anaesthesia, median (IQR), min   264.0 (228.8--313.3)     217.0 (176.5--244.3)   8 (8.3)       **\< 0.001**
  Conversion                                   0 (0.0%)                 5 (10.4%)              0 (0.0)       0.056[\*](#codi14601-note-0007){ref-type="fn"}
  Construction of anastomosis                                                                                
  Hand‐sewn                                    7 (14.6%)                0 (0.0%)               0 (0.0)       **0.012** [\*](#codi14601-note-0007){ref-type="fn"}
  Stapler                                      41 (85.4%)               48 (100.0%)                          
  Configuration of anastomosis                                                                               
  Side‐to‐end                                  26 (54.2%)               41 (85.4%)             3 (3.1)       **\< 0.001** [\*](#codi14601-note-0007){ref-type="fn"}
  End‐to‐end                                   20 (41.7%)               4 (8.3%)                             
  End‐to‐side                                  0 (0.0%)                 2 (4.2%)                             
  Diverting ileostomy                          40 (83.3%)               23 (47.9%)             0 (0.0)       **\< 0.001**
  CRM involvement                              2 (4.2%)                 1 (2.1%)               10 (10.4)     1.000[\*](#codi14601-note-0007){ref-type="fn"}
  DRM involvement                              5 (10.4%)                8 (16.7%)              8 (8.3)       0.322

CRM, circumferential resection margin; DRM, distal resection margin; IQR, interquartile range; LaTME, laparoscopic total mesorectal excision; TaTME, transanal total mesorectal excision.

Fisher\'s exact test.

Bold values indicates *P* value \<0.05.

John Wiley & Sons, Ltd

No statistically significant differences were observed for hospital stay, anastomotic leakage, ileus, cardiopulmonary complications, wound infections, Clavien--Dindo classification, CCI, readmissions, reoperations and mortality (Table [4](#codi14601-tbl-0004){ref-type="table"}). Readmissions were due to anastomotic leakage, high output stoma, ileus, pancreatic pseudocyst and iatrogenic small bowel perforation. The indications for reoperations were anastomotic leakage and replacement of diverting ileostomy. In the LaTME group, one patient died 2 days after discharge of an unknown reason as autopsy was not performed.

###### 

Postmatching postoperative course comparison

                                                   TaTME 48           LaTME 48          Missing (%)   *P* value
  ------------------------------------------------ ------------------ ----------------- ------------- ------------------------------------------------
  Hospital stay, median (IQR), days                8.0 (6.0--13.5)    7.5 (5.0--13.8)   0 (0.0)       0.596
  Anastomotic leakage                              10 (20.8%)         9 (18.8%)         0 (0.0)       0.798
  Ileus                                            7 (14.6%)          8 (16.7%)         0 (0.0)       0.779
  Cardiopulmonary complications                    0 (0.0%)           3 (6.3%)          0 (0.0)       0.242[\*](#codi14601-note-0009){ref-type="fn"}
  Wound infection                                  2 (4.2%)           1 (2.1%)          0 (0.0)       1.000[\*](#codi14601-note-0009){ref-type="fn"}
  Clavien--Dindo classification \> II              9 (18.8%)          10 (20.8%)        0 (0.0)       0.798
  Comprehensive complication index, median (IQR)   14.8 (0.0--22.6)   4.4 (0.0--22.6)   0 (0.0)       0.602
  Readmission                                      10 (20.8%)         5 (10.4%)         0 (0.0)       0.160
  Reoperation                                      8 (16.7%)          7 (14.6%)         0 (0.0)       0.779
  Mortality                                        0 (0.0%)           1 (2.1%)          0 (0.0)       1.000[\*](#codi14601-note-0009){ref-type="fn"}

IQR, interquartile range; LaTME, laparoscopic total mesorectal excision; TaTME, transanal total mesorectal excision.

Fisher\'s exact test.

John Wiley & Sons, Ltd

In the overall study population of 220 patients, multivariate penalized regression analyses showed that surgical approach is not associated with Clavien--Dindo classification \> II (OR 1.02, 95% CI 0.41--2.51, *P* = 0.970), CCI (estimate −0.77, 95% CI −6.84 to 5.31, *P* = 0.805), readmission (OR 1.13, 95% CI 0.43--2.99, *P* = 0.802) and reoperation (OR 1.33, 95% CI 0.49--3.64, *P* = 0.574; Table [5](#codi14601-tbl-0005){ref-type="table"}).

###### 

Multivariate penalized logistic regression to test the association between approach and Clavien--Dindo \> II, readmission and reoperation

+-----------------------------------+----------------------+-----------+-----------------+-------------+------------+-------+------------+-----------+
|                                   | Clavien--Dindo \> II | CCI       | Readmission     | Reoperation |            |       |            |           |
+===================================+======================+===========+=================+=============+============+=======+============+===========+
| Age, median (IQR), years          | 0.96                 | **0.014** | −0.32           | **0.008**   | 0.97       | 0.181 | 0.96       | **0.032** |
|                                   |                      |           |                 |             |            |       |            |           |
|                                   | 0.92--0.99           |           | −0.55 to −0.08  |             | 0.94--1.01 |       | 0.92--1.00 |           |
+-----------------------------------+----------------------+-----------+-----------------+-------------+------------+-------+------------+-----------+
| Gender                            | 0.77                 | 0.482     | −0.76           | 0.760       | 0.88       | 0.770 | 1.01       | 0.980     |
|                                   |                      |           |                 |             |            |       |            |           |
|                                   | 0.37--1.59           |           | −5.66 to 4.14   |             | 0.39--2.02 |       | 0.44--2.31 |           |
+-----------------------------------+----------------------+-----------+-----------------+-------------+------------+-------+------------+-----------+
| BMI, median (IQR), kg/m^2^        | 0.98                 | 0.550     | 0.06            | 0.820       | 0.98       | 0.618 | 1.03       | 0.588     |
|                                   |                      |           |                 |             |            |       |            |           |
|                                   | 0.90--1.06           |           | −0.45 to 0.57   |             | 0.89--1.07 |       | 0.94--1.12 |           |
+-----------------------------------+----------------------+-----------+-----------------+-------------+------------+-------+------------+-----------+
| Location lesion, median (IQR), cm | 1.00                 | 0.990     | 0.23            | 0.417       | 1.06       | 0.171 | 0.96       | 0.385     |
|                                   |                      |           |                 |             |            |       |            |           |
|                                   | 0.92--1.08           |           | −0.32 to 0.78   |             | 0.97--1.16 |       | 0.87--1.05 |           |
+-----------------------------------+----------------------+-----------+-----------------+-------------+------------+-------+------------+-----------+
| pT                                | 0.88                 | 0.455     | −0.76           | 0.514       | 0.94       | 0.774 | 1.01       | 0.952     |
|                                   |                      |           |                 |             |            |       |            |           |
|                                   | 0.62--1.24           |           | −3.03 to 1.51   |             | 0.64--1.39 |       | 0.68--1.50 |           |
+-----------------------------------+----------------------+-----------+-----------------+-------------+------------+-------+------------+-----------+
| Neoadjuvant radiotherapy          | 0.97                 | 0.939     | 1.63            | 0.585       | 1.05       | 0.920 | 0.86       | 0.748     |
|                                   |                      |           |                 |             |            |       |            |           |
|                                   | 0.41--2.26           |           | −4.21 to 7.47   |             | 0.41--2.70 |       | 0.34--2.16 |           |
+-----------------------------------+----------------------+-----------+-----------------+-------------+------------+-------+------------+-----------+
| Neoadjuvant chemotherapy          | 0.67                 | 0.391     | −7.09           | **0.026**   | 0.80       | 0.664 | 0.45       | 0.153     |
|                                   |                      |           |                 |             |            |       |            |           |
|                                   | 0.26--1.68           |           | −13.30 to −0.88 |             | 0.30--2.16 |       | 0.15--1.34 |           |
+-----------------------------------+----------------------+-----------+-----------------+-------------+------------+-------+------------+-----------+
| Diverting ileostomy               | 0.56                 | 0.151     | 1.12            | 0.680       | 2.22       | 0.107 | 0.41       | 0.054     |
|                                   |                      |           |                 |             |            |       |            |           |
|                                   | 0.26--1.23           |           | −4.19 to 6.43   |             | 0.84--5.83 |       | 0.17--1.01 |           |
+-----------------------------------+----------------------+-----------+-----------------+-------------+------------+-------+------------+-----------+
| Approach                          | 1.02                 | 0.970     | −0.77           | 0.805       | 1.13       | 0.802 | 1.33       | 0.574     |
|                                   |                      |           |                 |             |            |       |            |           |
|                                   | 0.41--2.51           |           | −6.84 to 5.31   |             | 0.43--2.99 |       | 0.49--3.64 |           |
+-----------------------------------+----------------------+-----------+-----------------+-------------+------------+-------+------------+-----------+

BMI, body mass index; CCI, comprehensive complication index; IQR, interquartile range.

Bold values indicates *P* value \<0.05.

John Wiley & Sons, Ltd

Discussion and conclusions {#codi14601-sec-0011}
==========================

This propensity score matched study of a prospective multicentre cohort study aimed to compare postoperative morbidity between TaTME and LaTME. Our results suggest that TaTME is a safe and feasible approach for rectal cancer resection and has similar postoperative morbidity to LaTME.

Nowadays, high conversion rates from laparoscopic to open surgery are reported for rectal resection especially in elderly patients and obese patients contributing to postoperative morbidity [6](#codi14601-bib-0006){ref-type="ref"}. Even in the most recent clinical trials comparing laparoscopic *vs* robotic assisted TME for rectal cancer, conversions were up to 10% in both arms [19](#codi14601-bib-0019){ref-type="ref"}. This is one of the main drawbacks of conventional laparoscopic surgery for rectal resection. In the present study, TaTME was not converted at all whilst LaTME was converted to laparotomy in 10.4% of cases. A recent single‐centre case‐matched study reported similar results [20](#codi14601-bib-0020){ref-type="ref"}. This low incidence of conversion seems to be the main advantages of this new technique.

With the introduction of minimally invasive techniques, the short‐term outcomes of rectal surgery have improved over recent decades. Despite these advances, the incidence of anastomotic leakage has not been reduced [21](#codi14601-bib-0021){ref-type="ref"}. Anastomotic leakage is one of the major concerns after rectal resection because of associated morbidity and mortality. A recent study demonstrated that large rectal tumours in obese, diabetic male patients who smoke have the highest risk for anastomotic leakage after TaTME [22](#codi14601-bib-0022){ref-type="ref"}. In line with previous literature, we found no difference in leakage rate for TaTME and LaTME [9](#codi14601-bib-0009){ref-type="ref"}, [10](#codi14601-bib-0010){ref-type="ref"}, [11](#codi14601-bib-0011){ref-type="ref"}, [13](#codi14601-bib-0013){ref-type="ref"}, [23](#codi14601-bib-0023){ref-type="ref"}, [24](#codi14601-bib-0024){ref-type="ref"}, [25](#codi14601-bib-0025){ref-type="ref"}. Therefore, the transanal approach does not seem to reduce the incidence of anastomotic leakage after rectal cancer resection.

In contrast to previous studies, our results show that TaTME is associated with more prolonged surgery and anaesthesia [7](#codi14601-bib-0007){ref-type="ref"}, [8](#codi14601-bib-0008){ref-type="ref"}. Previously, it was suggested that TaTME can be performed by two teams simultaneously; however, not all hospitals have the capacity to perform TaTME in two teams due to lack of personnel. When TaTME is not performed with two teams simultaneously, this may result in prolonged duration of surgery and anaesthesia. Moreover, this study included hospitals in which the TaTME technique was recently introduced. Therefore, a longer duration of surgery might reflect a learning curve [26](#codi14601-bib-0026){ref-type="ref"}. In addition, creation of a diverting ileostomy, which was more often performed in the TaTME group, may also influence duration of surgery and anaesthesia.

After matching for propensity score, patients who underwent LaTME received neoadjuvant radiotherapy more frequently than TaTME patients. The ESMO clinical practice guidelines have recently been updated indicating that specific patients with intermediate risk rectal cancer do not need neoadjuvant treatment in order to minimize local recurrence if good quality TME can be achieved [27](#codi14601-bib-0027){ref-type="ref"}. Since TaTME has recently become more popular, this difference might mirror the update of these guidelines. In addition, this study showed, in the unmatched cohort, that preoperative radiotherapy was not associated with postoperative morbidity (Table [5](#codi14601-tbl-0005){ref-type="table"}), and therefore it is unlikely that this difference in baseline characteristics has influenced the results.

In the postmatching TaTME group, more manual and end‐to‐end anastomoses were observed, even though there were no baseline differences between the two groups on tumour height. A systematic review showed similar results [28](#codi14601-bib-0028){ref-type="ref"}.

Diverting ileostomies are common after rectal resection but do not reduce anastomotic leakage or mortality [29](#codi14601-bib-0029){ref-type="ref"}. In fact, diverting ileostomies tend to mitigate the consequences of anastomotic leakage resulting in less invasive treatment strategies. In the present study, patients who underwent TaTME were more often diverted during primary surgery. A recent single‐centre case‐matched study found similar results [25](#codi14601-bib-0025){ref-type="ref"}. This difference might reflect surgeons' perception to protect the anastomosis following the new approach whilst this risk is unsubstantiated.

In the present study, tumour location was derived from endoscopy. There seems to be a significant difference between the tumour location of colorectal cancers reported by endoscopy and the actual location determined during surgery [30](#codi14601-bib-0030){ref-type="ref"}. Moreover, the anal verge was the reference for determination of the tumour location. Thus, this distance includes the anal canal of 3--5 cm [31](#codi14601-bib-0031){ref-type="ref"}. This may explain the relatively high tumour location in both the TaTME and the LaTME groups.

Functional outcomes are of interest for future research. TaTME possibly provides better visualization of the distal rectum which may contribute to preservation of pelvic nerves and vascularity resulting in better urinary and sexual function [23](#codi14601-bib-0023){ref-type="ref"}, [32](#codi14601-bib-0032){ref-type="ref"}.

At this moment, this subgroup analysis provides the highest level of evidence on postoperative short‐term results after TaTME and LaTME currently available since the results are based on a multicentre prospective cohort study. Nevertheless, we recognize several limitations of the study. First, the TME procedures in both groups were not standardized so different types of laparoscopic assisting techniques (i.e. single‐port or multi‐port) were used. Second, cohort studies are sensitive to bias and confounding. Nevertheless, both propensity score analysis and penalized multivariate regression analyses were performed to adjust for confounding effects showing similar results.

This propensity score matched study of a prospective multicentre cohort study aimed to compare postoperative morbidity between TaTME and LaTME. It was shown that TaTME is a safe and feasible approach for rectal cancer resection. This new technique obtained similar postoperative morbidity. This study is the first to provide evidence based upon prospective data. However, oncological safety in terms of CRM involvement and local recurrence should be obtained in a well‐designed randomized controlled trial.
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